Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trending Up: FDA’s Drug GMP Data Integrity Warning Letters

This article was originally published in The Gold Sheet

Executive Summary

See how the trend in FDA drug GMP warning letters has increased, both in terms of the number of warning letters and the number of countries where they went.

You may also be interested in...



Continuous Manufacturing Centers Of Excellence Measure Resurfaces In US House

Stand-alone bill headed for Senate, where it fared poorly in coronavirus response legislative packages.

COVID-19 Shows US FDA Why It Needs To Know Supply Chain’s Current And Surge Capacities

Agency begins gathering manufacturing plant data to prepare for disruptions that can drain inventories over a weekend.

US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline

With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel